Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study.
Grundy RG, Hutton C, Middleton H, Imeson J, Pritchard J, Kelsey A, Marsden HB, Vujanic GM, Taylor RE; United Kingdom Children's Cancer Study Group. Grundy RG, et al. Among authors: vujanic gm. Pediatr Blood Cancer. 2004 Apr;42(4):311-9. doi: 10.1002/pbc.10477. Pediatr Blood Cancer. 2004. PMID: 14966826 Clinical Trial.
Multiple pathways to Wilms tumor: how much is genetic?
Pritchard-Jones K, Vujanic G. Pritchard-Jones K, et al. Among authors: vujanic g. Pediatr Blood Cancer. 2006 Sep;47(3):232-4. doi: 10.1002/pbc.20948. Pediatr Blood Cancer. 2006. PMID: 16830319 No abstract available.
Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group.
van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R, Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic GM. van den Heuvel-Eibrink MM, et al. Pediatr Blood Cancer. 2011 May;56(5):733-7. doi: 10.1002/pbc.22922. Epub 2010 Dec 22. Pediatr Blood Cancer. 2011. PMID: 21370404
Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
Irtan S, Jitlal M, Bate J, Powis M, Vujanic G, Kelsey A, Walker J, Mitchell C, Machin D, Pritchard-Jones K; Renal Tumours Committee of the Children’s Cancer and Leukaemia Group (CCLG). Irtan S, et al. Among authors: vujanic g. Eur J Cancer. 2015 Jan;51(2):225-32. doi: 10.1016/j.ejca.2014.10.026. Epub 2014 Nov 22. Eur J Cancer. 2015. PMID: 25465191 Clinical Trial.
Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
Mavinkurve-Groothuis AM, van den Heuvel-Eibrink MM, Tytgat GA, van Tinteren H, Vujanic G, Pritchard-Jones KL, Howell L, Graf N, Bergeron C, Acha T, Catania S, Spreafico F. Mavinkurve-Groothuis AM, et al. Among authors: vujanic g. Pediatr Blood Cancer. 2015 Apr;62(4):598-602. doi: 10.1002/pbc.25357. Epub 2014 Dec 29. Pediatr Blood Cancer. 2015. PMID: 25546733 Clinical Trial.
Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Pritchard-Jones K, et al. Among authors: vujanic g. Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9. Lancet. 2015. PMID: 26164096 Free article. Clinical Trial.
161 results